secwatch.observer — SEC 8-K summary
======================================

Issuer:     CDT Equity Inc. (CDT)
CIK:        0001896212
Form:       8-K
Filed at:   2025-04-16T23:59:59+00:00
Accession:  0001641172-25-005036
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Conduit Pharma appoints founder Andrew Regan as CEO; Tapolczay transitions to licensing role
--------------------------------------------------------------------------------

- David Tapolczay resigned as CEO and board member effective April 12, 2025; to serve as Head of Licensing & Strategy at £240K salary.
- Andrew Regan appointed CEO effective April 15, 2025; continues as director and waives compensation except expense reimbursement.
- Faith Charles resigned from board effective April 16, 2025 for personal reasons; board reduced from seven to five members.
- Tapolczay to focus on out-licensing tapinarof patents; Regan highlights AI collaboration with Sarborg and 20-year patent strategy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1896212/000164117225005036/0001641172-25-005036-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1896212/000164117225005036/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-005036

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer